



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Briakinumab

Cat. No.:	HY-P99486
CAS No.:	339308-60-0
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis ^[1] .	
IC ₅₀ & Target	IL-12	IL-23
In Vitro	Briakinumab targets the p40 molecule shared by interleukin-12 and interleukin-23 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	

REFERENCES

- [1]. Panaccione R, et, al. Briakinumab for treatment of Crohn's disease: results of a randomized trial. *Inflamm Bowel Dis*. 2015 Jun;21(6):1329-40.
- [2]. Reich K, et, al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. *N Engl J Med*. 2011 Oct 27;365(17):1586-96.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA